Editas Medicine (NASDAQ:EDIT – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Editas Medicine to related companies based on the strength of its profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and earnings.
Insider and Institutional Ownership
71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Editas Medicine and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Editas Medicine | -157.32% | -196.63% | -38.17% |
| Editas Medicine Competitors | -12,357.18% | -197.96% | -30.56% |
Analyst Ratings
This is a summary of current ratings and price targets for Editas Medicine and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Editas Medicine | 1 | 0 | 6 | 0 | 2.71 |
| Editas Medicine Competitors | 9838 | 15122 | 45436 | 1587 | 2.54 |
Editas Medicine presently has a consensus target price of $5.83, suggesting a potential upside of 126.98%. As a group, “Biotechnology” companies have a potential upside of 102.62%. Given Editas Medicine’s stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than its peers.
Risk and Volatility
Editas Medicine has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Comparatively, Editas Medicine’s peers have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.
Valuation and Earnings
This table compares Editas Medicine and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Editas Medicine | $47.01 million | -$160.06 million | -3.43 |
| Editas Medicine Competitors | $728.25 million | $12.25 million | -15.19 |
Editas Medicine’s peers have higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Editas Medicine beats its peers on 8 of the 13 factors compared.
Editas Medicine Company Profile
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
